Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-SALVENT STERULES | 0.5MG | SOLUTION | Actual shortage | 2017-08-14 | 2017-10-05 | 19114 |
| APO-SALVENT TABLETS - 4MG | 4MG | TABLET | Resolved | 2017-03-12 | 2017-05-10 | 689 |
| APO-SALVENT-IPRAVENT STERULES | 0.5MG 2.5MG | SOLUTION | Actual shortage | 2017-08-14 | 2017-10-05 | 19323 |
| APO-SAXAGLIPTIN | 5MG | TABLET | Resolved | 2022-02-04 | 2022-07-11 | 154208 |
| APO-SAXAGLIPTIN | 2.5MG | TABLET | Resolved | 2022-01-14 | 2022-07-19 | 152773 |
| APO-SAXAGLIPTIN | 5MG | TABLET | Resolved | 2021-12-10 | 2022-01-31 | 150896 |
| APO-SAXAGLIPTIN | 5MG | TABLET | Resolved | 2024-10-24 | 2025-01-03 | 241063 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2023-11-17 | 2024-01-12 | 210683 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2017-11-28 | 2018-02-23 | 30963 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2024-05-24 | 2024-07-05 | 228786 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2018-07-16 | 2018-08-31 | 55847 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2020-04-15 | 2020-05-11 | 112195 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2024-03-27 | 2024-04-12 | 223540 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2023-11-10 | 2024-01-19 | 209945 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2021-10-01 | 2021-12-06 | 146514 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2024-08-09 | 2024-09-06 | 234992 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2017-11-28 | 2018-01-18 | 30967 |
| APO-SERTRALINE | 100MG | CAPSULE | Resolved | 2017-11-09 | 2018-01-31 | 28709 |
| APO-SERTRALINE | 25MG | CAPSULE | Resolved | 2017-06-13 | 2017-10-12 | 12698 |
| APO-SERTRALINE | 50MG | CAPSULE | Resolved | 2018-02-21 | 2018-06-12 | 40377 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |